Submitted by pgmcintosh on Mon, 29/06/2009 - 13:26
Following concerns raised by another paper in Diabetologia the EASD asked a team of researchers in Scotland (the Scottish Diabetes Research Network – Epidemiology group) to examine the question of cancer risk in insulin glargine users in Scotland.
Using anonymised patient data linked to the Scottish Cancer Registry Data we were able to show that insulin glargine users as a whole do not have an altered risk of all cancers combined or any of the main cancers, including breast cancer. This is reassuring news.